Short interest for Actavia Life Sciences gives investors a sense of the degree to which investors are betting on the decline of Actavia Life Sciences's stock. Short interest data is updated every two weeks.

Actavia Life Sciences Stock Short Interest Report | OTC:RASP | Benzinga

ACTAVIA LIFE SCIENCES INC by Actavia Life Sciences, Inc.

Actavia Life Sciences Inc

RASPBERRY PI HLDGS PLC by RASPBERRY PI HLDGS PLC

Actavia Life Sciences

Overview

Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Comments

Actavia Life Sciences Short Interest Report

Actavia Life Sciences Stock Short Interest Report | OTC:RASP | Benzinga